EU/3/12/999

About

On 6 June 2012, orphan designation (EU/3/12/999) was granted by the European Commission to AiCuris GmbH & Co. KG, Germany, for letermovir for the treatment of cytomegalovirus disease in patients with impaired cell-mediated immunity.

The sponsorship was transferred to Merck Sharp & Dohme Limited, United Kingdom, in March 2013.

The sponsorship was transferred to Merck Europe B.V., The Netherlands, in June 2018.

Key facts

Active substance
Letermovir
Disease / condition
Treatment of cytomegalovirus disease in patients with impaired cell-mediated immunity
Date of decision
06/06/2012
Outcome
Positive
Orphan decision number
EU/3/12/999

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Merck Europe B.V.
Waarderweg 39
2031 BN Haarlem
The Netherlands
Tel: +31235153260
E-mail: orphan.information@merck.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating